Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ligilactobacillus salivarius LS01
- Development stage
- Unknown
- Lead developer
- Probiotical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Ligilactobacillus salivarius LS01 (formerly Lactobacillus salivarius LS01) is a specific probiotic bacterial strain (DSM 22775) developed by Probiotical S.p.A. as a live biotherapeutic product. It is primarily investigated for the treatment of inflammatory conditions, most notably atopic dermatitis in both pediatric and adult populations, as well as pediatric asthma. The strain functions by modulating the host's immune response, specifically by shifting the T-helper cell balance from a Th2-dominant state toward a Th1-dominant state, thereby reducing the production of pro-inflammatory cytokines (such as IL-4 and IL-5) and increasing or stabilizing Th1 cytokines (such as IFN-gamma and IL-12). Additionally, it exhibits antimicrobial activity, particularly in reducing the load of pathogenic Staphylococcus species in the intestinal microbiota, which is linked to improvements in skin barrier function and clinical symptoms like the SCORAD index and pruritus.
- Brand names
- LS01™
- Other names
- Lactobacillus salivarius LS01L. salivarius LS01
02
Targets
IL-4 (Interleukin 4)IL-5 (Interleukin 5)IFNG (Interferon gamma)IL12 (Interleukin-12)
Beyond the preview
Go deeper on ligilactobacillus salivarius LS01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ligilactobacillus salivarius LS01.